Evidence map›Paper›PMID 38147272›Full record

ArticleBrain imaging and behavior2024

Connectome architecture modulates the gray matter atrophy in major depression disorder patients with diverse suicidal ideations.

Shengli Chen, Xiaojing Zhang, Shiwei Lin, Yingli Zhang, Ziyun Xu, Yanqing Li, Manxi Xu, Gangqiang Hou, Yingwei Qiu

Abstract read
PubMed Publisher
In one paragraph

Article in Brain imaging and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shengli Chen *Department of Radiology, Huazhong University of Science and Technology Union Shenzhen Hospital, Taoyuan AVE 89, Nanshan District, Shenzhen, 518000, People's Republic of China.
Xiaojing ZhangGuangdong Provincial Key Laboratory of Genome Stability and Disease Prevention and Regional Immunity and Diseases, Department of Pathology, Shenzhen University School of Medicine, Shenzhen, 518060, People's Republic of China.
Shiwei LinDepartment of Radiology, Huazhong University of Science and Technology Union Shenzhen Hospital, Taoyuan AVE 89, Nanshan District, Shenzhen, 518000, People's Republic of China.
Yingli Zhang *Department of Depressive Disorders, Shenzhen Mental Health Center, Shenzhen Kangning Hospital, Cuizhu AVE 1080, Luohu District, Shenzhen, 518020, People's Republic of China.
Ziyun XuDepartment of Radiology, Shenzhen Mental Health Center, Shenzhen Kangning Hospital, Cuizhu AVE 1080, Luohu District, Shenzhen, 518020, People's Republic of China.
Yanqing LiDepartment of Radiology, Huazhong University of Science and Technology Union Shenzhen Hospital, Taoyuan AVE 89, Nanshan District, Shenzhen, 518000, People's Republic of China.
Manxi XuDepartment of Radiology, Huazhong University of Science and Technology Union Shenzhen Hospital, Taoyuan AVE 89, Nanshan District, Shenzhen, 518000, People's Republic of China.
Gangqiang HouDepartment of Radiology, Shenzhen Mental Health Center, Shenzhen Kangning Hospital, Cuizhu AVE 1080, Luohu District, Shenzhen, 518020, People's Republic of China. nihaohgq@163.com.
Yingwei QiuDepartment of Radiology, Huazhong University of Science and Technology Union Shenzhen Hospital, Taoyuan AVE 89, Nanshan District, Shenzhen, 518000, People's Republic of China. qiuyw1201@gmail.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2022A1515012503Nanshan District Health System Technology Major Project NSZD2023025Natural Scientific Foundation of China 81560283 and 81201084Scientific and Technological Projects of Nanshan NS2022007Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties No. SZGSP013Shenzhen Key Medical Discipline Construction Fund No.SZXK041
6 · The paper itself

Abstract

Gray matter (GM) atrophy is well documented in patients with major depressive disorder (MDD), but its underlying mechanism remains unknown. This study aimed to examine the GM atrophy in MDD patients with diverse suicidal ideations (SIs) and to explore whether those alterations were driven by connections. GM volume was estimated in 163 patients with recurrent MDD (comprising 122 with SI [MDDSI] and 41 without SI [MDDNSI]) and 134 health controls (HCs). A two-sample t-test was used to identify GM volume abnormalities in MDD patients and their subgroups. Functional connectivity was computed between pairs of aberrant GM in both patients and HCs, which were further compared with the connectivity of random brain regions. A permutation test was performed to assess its significance. Propensity score matching (PSM) was further performed to validate the main results. Compared with HCs, the MDDNSI group exhibited GM atrophy in 24 regions, with the largest effect sizes found in the frontal and parietal lobes, while the MDDSI group exhibited more widespread GM atrophy involving 49 regions, with the largest effect sizes in the frontal lobe, parietal lobe, temporal lobe, and the limbic system. Furthermore, patients and HCs exhibited significantly increased functional connectivity between regions with GM atrophy compared with randomly selected regions (p < 0.05). PSM analysis presented similar results to the main analysis. MDD patients had diverse GM atrophy features according to their SI tendency. Moreover, connectome architecture modulates the GM atrophy in MDD patients, implying the possibility that connections drive these pathological changes.

Indexed as

AtrophyBrainConnectomeGray MatterMagnetic Resonance ImagingMajor Depressive DisorderSuicidal IdeationAdultFemaleHumansMaleMiddle AgedNeural PathwaysConnectivityGray matterMajor depressive disorderSuicidal ideation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.